Avery Therapeutics, Inc.

Company profile

Avery Therapeutics, Inc. company profile

Avery Therapeutics, Inc. is a company dedicated to developing tissue engineered therapeutics to treat diseases and injuries to human muscle.  Avery’s lead product, MyCardia™, is being developed to address and treat heart failure. More than 23 million people worldwide suffer from heart failure – the number one cause of morbidity and mortality in the developed world. In the United States, heart failure is projected to result in over $70B in treatment costs annually. MyCardia is a stable and robust allogeneic engineered tissue graft that can be manufactured at scale, cryopreserved, and shipped at room temperature.  In pre-clinical studies of heart failure, MyCardia resulted in improved left ventricular volume (systole and diastole) and myocardial mass, in addition to improved quality of life metrics such as daily activity and exercise tolerance, compared to untreated cohorts.